Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib

被引:44
作者
Hemeryck, Alex [1 ]
Geerts, Rita
Monbaliu, Johan
Hassler, Stephan
Verhaeghe, Tom
Diels, Luc
Verluyten, Willy
van Beijsterveldt, Ludy
Mamidi, Rao N. V. S.
Janssen, Cor
De Coster, Roland
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Global Preclin Dev, Beerse, Belgium
[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
[3] RCC Ltd, Environm Chem & Pharmanalayt Div, Itingen, Switzerland
关键词
bortezomib; VELCADE; rat; biodistribution; repeated dosing;
D O I
10.1007/s00280-007-0424-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus) administration with C-14-labelled bortezomib (VELCADE (R)) (0.2 mg/kg; 0.28 MBq./kg). Methods Bortezomib was dosed on days 1, 4, 8, and 11 (i.e. a clinical dosing cycle) and the animals were sacrificed at selected time points following single and repeated dose administration for the quantification of TR in blood, plasma, and various tissues by liquid scintillation counting following organ dissection or by quantitative whole body autoradiography. In selected tissues, bortezomib levels were determined by LC-MS/MS. Results In general, plasma TR levels were less than 10% of the corresponding blood concentrations. TR was rapidly and widely distributed to the tissues with only limited penetration into the central nervous system (CNS). In the tissues, highest levels of TR were measured in bortezomib-eliminating organs (liver and kidney), lymphoid tissues, and regions of rapidly dividing cells (e.g. the bone marrow, intestinal mucosa). Low TR concentrations were found in the CNS (tissue-to-blood ratio of similar to 0.05 after repeated dosing). With the exception of the liver, TR consisted almost exclusively of the parent drug. Tissue concentrations of TR and bortezomib increased up to about threefold from the first to the third dose administration, after which they remained constant. Conclusion No undue tissue accumulation of TR and of bortezomib was observed in rats following a full clinical dosing cycle of bortezomib.
引用
收藏
页码:777 / 787
页数:11
相关论文
共 17 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   The aggravating role of the ubiquitin-proteasome system in neurodegeneration [J].
Ardley, HC ;
Hung, CC ;
Robinson, PA .
FEBS LETTERS, 2005, 579 (03) :571-576
[3]   Approval summary for bortezomib for injection in the treatment of multiple myeloma [J].
Bross, PF ;
Kane, R ;
Farrell, AT ;
Abraham, S ;
Benson, K ;
Brower, ME ;
Bradley, S ;
Gobburu, JV ;
Goheer, A ;
Lee, SL ;
Leighton, J ;
Liang, CY ;
Lostritto, RT ;
McGuinn, WD ;
Morse, DE ;
Rahman, A ;
Rosario, LA ;
Verbois, SL ;
Williams, G ;
Wang, YC ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :3954-3964
[4]  
Daniels JS, 2003, DRUG METAB REV, V35, P44
[5]  
Food and Drug Administration (FDA), 2001, BIOAN METH VAL
[6]  
*ICH CPMP, 1994, CPMPICH38595
[7]   Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies [J].
Ludwig, H ;
Khayat, D ;
Giaccone, G ;
Facon, T .
CANCER, 2005, 104 (09) :1794-1807
[8]   Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease [J].
McNaught, KSP ;
Perl, DP ;
Brownell, AL ;
Olanow, CW .
ANNALS OF NEUROLOGY, 2004, 56 (01) :149-162
[9]   Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma [J].
Miyakoshi, S ;
Kami, M ;
Yuji, K ;
Matsumura, T ;
Takatoku, M ;
Sasaki, M ;
Narimatsu, H ;
Fujii, T ;
Kawabata, M ;
Taniguchi, S ;
Ozawa, K ;
Oshimi, K .
BLOOD, 2006, 107 (09) :3492-3494
[10]   Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment [J].
Montagut, C ;
Rovira, A ;
Mellado, B ;
Gascon, P ;
Ross, JS ;
Albanell, J .
DRUGS OF TODAY, 2005, 41 (05) :299-315